New York, January 10, 2026, 14:52 EST — Market closed.
- Philip Morris shares closed Friday 2.39% higher at $162.61, marking a second consecutive rise on light volume.
- UBS stuck with a Neutral rating and a $158 target, citing increased competition in nicotine pouches and heated tobacco products.
- Key upcoming dates include the Jan. 14 dividend payout, the Jan. 22 FDA advisory meeting on ZYN’s “modified-risk” claim, and quarterly results due Feb. 5.
Philip Morris International shares climbed for a second day on Friday, closing up 2.39% at $162.61. Volume hit roughly 4.4 million shares, falling short of the stock’s 50-day average. The S&P 500 and Dow also finished higher. (MarketWatch)
Why it matters now: PM has shifted into a smoke-free growth play in an industry usually defined by cash flow and regulation. Any sign of weakening demand or pricing power tends to hit the stock quickly.
UBS analyst Faham Baig stuck with a Neutral rating and kept his $158 price target on Philip Morris on Friday. He warned the company’s 2026 results could fall short of its mid-term goals. Baig projected organic sales growth of 5.7% in 2026, excluding currency shifts and deals, while EBIT growth would hit 7.0%. He flagged a sluggish start to the year, citing tougher competition in nicotine pouches and challenges in Japan’s heated-tobacco segment. (Investing.com)
PM remains on a gradual climb back from its mid-year highs. Nasdaq data lists its 52-week range between $116.12 and $186.69, with shares currently sitting in the upper half as next week approaches. (Nasdaq)
The larger tobacco sector followed suit. Altria climbed 2.92% on Friday, beating Philip Morris, as investors favored defensive stocks late in the week. (MarketWatch)
Regulation could move quickly. On Jan. 22, the U.S. Food and Drug Administration will hold an advisory committee meeting to assess Swedish Match USA’s request to market certain ZYN nicotine pouches as lower-risk than cigarettes. This decision might heavily influence how aggressively these products can be promoted. The company’s proposed claim states: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” (Reuters)
Philip Morris is set to release its fourth-quarter 2025 earnings on Feb. 5. Investors will be listening closely for any early insights on 2026 volumes, price/mix dynamics, and investments in smoke-free products. (Pmi)
Cash returns remain a key draw. Philip Morris plans to pay a $1.47-per-share quarterly dividend on Jan. 14, per its dividend schedule. (Pmi)
On the downside, if competition in pouches sparks a price war, or if the FDA delays or denies modified-risk status for ZYN, the stock’s lofty valuation might start to feel shaky. That’s especially true if PM’s 2026 growth more closely resembles “steady staples” rather than the hoped-for “smoke-free growth.”
Traders are now focused on the Jan. 22 FDA advisory committee meeting on ZYN, with Philip Morris’ Feb. 5 quarterly results set to provide the next big update on 2026 momentum.
